This presentation was made by Valérie Paris, OECD Secretariat, at the 6th meeting of the joint OECD DELSA-GOV network on fiscal sustainability of health systems held in Paris, on 18-19 September 2017
Advanced technologies and budgetary implications -- Vadim Perman, IsraelOECD Governance
This presentation was made by Vadim Perman, Israel, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Valerie Paris, OECDOECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Thomas Baardseng, ...OECD Governance
This presentation was made by Thomas Baardseng, Norway, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Productivity in the health sector -- Peter Smith, United KingdomOECD Governance
This presentation was made by Peter Smith, United Kingdom, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Saudi Arabia has the largest healthcare market in the GCC due to high population growth, aging population, and diseases related to lifestyle. The government spends over $28 billion annually on healthcare and aims to increase capacity and quality through privatization, insurance reforms, and regulatory changes. There are many investment opportunities in hospitals, medical cities, specialized care, diagnostics, manufacturing, insurance, education, e-health, and partnerships with international companies. The healthcare sector is moving from a national system to a more private and market-driven system to meet the growing demands of the population.
2B Kalfhaus Opportunities and Challenges of Telemedicine EHiN 2014IKT-Norge
Lars Kalfhaus
Country Manager Roche Diabetes Care (ES)
Connect, Engage and Take Decisions
Opportunities and Challenges of Telemedicine Implementation
EHiN 2014, IKT-Norge og HOD
The document provides an analysis of business opportunities for Philips Healthcare in Sri Lanka. It summarizes the current healthcare landscape and market potential in Sri Lanka. It evaluates different business models for Philips' operations in Sri Lanka and proposes establishing a branch office (Model 4) to gain customer confidence and address the fast growth in healthcare demand. The justification discusses registering a company, taxes, and possible tax exemptions available. It indicates setting up a branch office would help Philips strengthen its presence and better address the needs of the growing Sri Lankan healthcare sector.
Health Care and Diagnostics Sector Saudi Arabia - Opportunity Arabia 11, 2014Odyssey Recruitment
This presentation was shown at Opportunity Arabia 11, 2014. It looks at the Saudi Arabian Health Care Sector and the opportunities in this sector for UK businesses. The sector is developing quickly and there are opportunities in all areas but especially high tech medicine, diagnostic equipment, IT and hospital management.
Advanced technologies and budgetary implications -- Vadim Perman, IsraelOECD Governance
This presentation was made by Vadim Perman, Israel, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Valerie Paris, OECDOECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Thomas Baardseng, ...OECD Governance
This presentation was made by Thomas Baardseng, Norway, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Productivity in the health sector -- Peter Smith, United KingdomOECD Governance
This presentation was made by Peter Smith, United Kingdom, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Saudi Arabia has the largest healthcare market in the GCC due to high population growth, aging population, and diseases related to lifestyle. The government spends over $28 billion annually on healthcare and aims to increase capacity and quality through privatization, insurance reforms, and regulatory changes. There are many investment opportunities in hospitals, medical cities, specialized care, diagnostics, manufacturing, insurance, education, e-health, and partnerships with international companies. The healthcare sector is moving from a national system to a more private and market-driven system to meet the growing demands of the population.
2B Kalfhaus Opportunities and Challenges of Telemedicine EHiN 2014IKT-Norge
Lars Kalfhaus
Country Manager Roche Diabetes Care (ES)
Connect, Engage and Take Decisions
Opportunities and Challenges of Telemedicine Implementation
EHiN 2014, IKT-Norge og HOD
The document provides an analysis of business opportunities for Philips Healthcare in Sri Lanka. It summarizes the current healthcare landscape and market potential in Sri Lanka. It evaluates different business models for Philips' operations in Sri Lanka and proposes establishing a branch office (Model 4) to gain customer confidence and address the fast growth in healthcare demand. The justification discusses registering a company, taxes, and possible tax exemptions available. It indicates setting up a branch office would help Philips strengthen its presence and better address the needs of the growing Sri Lankan healthcare sector.
Health Care and Diagnostics Sector Saudi Arabia - Opportunity Arabia 11, 2014Odyssey Recruitment
This presentation was shown at Opportunity Arabia 11, 2014. It looks at the Saudi Arabian Health Care Sector and the opportunities in this sector for UK businesses. The sector is developing quickly and there are opportunities in all areas but especially high tech medicine, diagnostic equipment, IT and hospital management.
This document provides an overview of health technology assessment (HTA) through a presentation given at the 62nd Session of the WHO Regional Committee for the Eastern Mediterranean. It defines HTA and its goals of providing evidence-informed input to decision makers and ensuring value for money. The presentation outlines how HTA is a multidisciplinary activity that examines the effects of health technologies on resources, costs, technical aspects, and other issues. It provides examples of HTA implementation from Thailand, Iran, and other countries. The presentation calls for all countries to establish national HTA programs and capacities and emphasizes that HTA is especially important for resource-limited settings. It outlines future commitments and steps from member states and WHO to strengthen HTA in the
Pauline Norris (University of Otago, New Zealand): Insight in the New Zealand health care system, with a focus on medicines – current status and developments. Kelan tutkimuksen "Lääke-euro talouden puristuksessa" -seminaari 3.6.2015, Helsinki.
New Zealand has a publicly funded healthcare system with universal coverage. It has a national electronic health record system including a unique patient identifier used for over 20 years. Most primary care practices use comprehensive electronic medical record systems integrated with labs and prescribing. Hospitals use integrated clinical workstations and patient administration systems. The national health IT plan aims to achieve high quality integrated care through shared care programs and national clinical systems like ePrescribing. Standards are developed through HISO and openEHR is used to define content and enable data sharing and secondary use through a shared health information platform.
This document discusses the Independent Hospital Pricing Authority's (IHPA) work on pricing reforms beyond 2020. Key points include:
1) IHPA sets national efficient prices, develops classification systems, and handles cross-border disputes to promote transparency, value, and efficiency in the public hospital system.
2) IHPA is moving public hospital funding toward an activity-based funding model, with blocks of funding still used in some areas. This has led to a significant slowdown in cost growth.
3) IHPA is developing pricing approaches to incentivize safety, quality and efficiency. This includes not funding episodes involving sentinel events, paying less for episodes complicated by hospital-acquired conditions,
The document discusses the OECD Recommendation on Health Data Governance. It notes that better policy frameworks are needed to make more effective use of health data. The recommendation was developed over two years with input from governments, civil society, and industry. It aims to establish national health data governance frameworks, promote privacy and data security, and enable cross-country research and statistics. The recommendation includes provisions around transparency, consent, oversight, and monitoring progress on implementation.
Spending reviews: OECD practices and applications for healthOECD Governance
This presentation was made by Ronnie DOWNES, OECD Secretariatat the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems held on 4-5 February 2016 at the OECD Conference Centre in Paris.
The drivers of public health spending: integrating policies and institutionsOECD Governance
This presentation was made by Joaquim Oliveira Martins at the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems, held on 4-5 February 2016 at the OECD Conference Centre in Paris.
The document provides an overview of health technology assessment (HTA) reports produced by the Malaysian Health Technology Assessment Section (MaHTAS). It discusses MaHTAS's functions, products, and processes for conducting HTAs. Key points include that MaHTAS has produced over 550 HTA reports since 1997 covering various health technologies. The document also outlines criteria for evaluating the quality of HTA reports based on a checklist from the International Network of Agencies for HTA, focusing on transparency around methods, sources of information, and conclusions.
Role of In Vitro Diagnostics in Saudi ArabiaSolidiance
Saudi Arabia’s healthcare system currently relies heavily on government funding, which accounts for 65% healthcare spending in the country. Healthcare trends in Saudi Arabia's, e.g. demographic shifts, high incidence rates of lifestyle related diseases, growing demand for private healthcare services, and strategic investments made by the government have driven demands for in vitro diagnostic (IVD) devices. Solidiance co-developed this exclusive white paper with Kind Abdulaziz Medical City and Abbott Diagnostics, highlighting the contribution, value and future of in vitro diagnostics in Saudi Arabia’s healthcare system. According to the report, the future looks bright for IVD in Saudi Arabia, however it depends on how fast it can be adopted and implemented in order to benefit the government, healthcare players seeking to improve and invest on the sector, and also the people.
This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian Towse
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
The document discusses healthcare spending in Malaysia relative to other countries. It notes that while Malaysia spends around 4% of GDP on healthcare, this is split almost evenly between public and private spending. There are pressures to increase healthcare spending due to an aging population and shift to chronic diseases. While additional investment may pay off through economic and health gains, funding needs to be increased through measures like taxes on tobacco or reducing fossil fuel subsidies. The large public-private divide and high out-of-pocket spending also need to be addressed through more strategic purchasing of healthcare services.
This presentation was made by Vlasta KOVACIC MEZEK, Slovenia, at the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems held on 4-5 February 2016 at the OECD Conference Centre in Paris.
Sri Lanka is well known for its better health indices when compared with other countries in South Asia. However, the burdens of Non Communicable Diseases (NCD) have increased rapidly during last two decades. NCDs such as neoplasms, cardiovascular diseases, diabetes and chronic respiratory pathologies recorded were 10.2, 41.7, 13.3 (related deaths per 100,000 population) respectively during the year 1990. However by 2009, the same NCDs recorded 18.5, 60.6, and 21.9 (related deaths per 100,000 populations) respectively according to the Annual Health Bullatin released by the Medical Statistics Unit - Ministry of Healthcare & Nutrition [1]. Most communicable diseases have been controlled successfully (e.g. Malaria, Polio) several infective diseases, such as, Tuberculosis and Leprosy has been re-emerged due to various reasons. Dengue is also still remains a major crisis in Sri Lankan health sector.
Health Information Systems have been shown an integral role in health systems in facing double burden of disease, specially quantifying the cost of care. Also, Health Information Systems are one of WHO's 6 building blocks for health system strengthening. This work investigates the Sri Lankan scenario empirically based on selected electronic health information systems to evaluate the effect of reducing uncertainty and promoting coordination in the clinical care pathway.
The document provides an overview of basic health economics concepts. It discusses 1) how health expenditures relate to overall economic growth, 2) how resources are allocated in healthcare systems to maximize efficiency, and 3) issues regarding the long-term sustainability of healthcare systems. Key points include how economic analysis can help optimize resource allocation to meet needs, how rising drug costs and an aging population impact sustainability, and the risk of a "trade war" over pharmaceutical prices between the US and other countries.
Professor Sue Hill OBE, Chief Scientific Officer for Englandrightcare
We are excited to introduce the NHS Atlas of Variation in Diagnostic Services, the latest publication in the series of impressive NHS Atlases, which have highlighted variation in the provision of healthcare services.
Diagnostic services are of great importance in the NHS because, when used correctly, they support or rule out potential diagnoses, and underpin the effective and efficient management of patient pathways.
Unwarranted variation in the rates of diagnostic testing is of the utmost relevance to individual patients with the over-use, as well as under-use, of diagnostic tests being potentially serious issues. For example, effective capacity planning in imaging services should enable improved patient access balanced against the need to avoid over-use of interventions that have the potential to cause harm, such as ionising radiation.
Chapter 13 national health information systemnaranbatn
1. The document discusses the national health information system in Korea and provides details on the community health information system, future e-health models, and hospital information systems.
2. It outlines Korea's plan for a national health information system, including developing health information standards, implementing an electronic health record system, and revising medical laws regarding e-health.
3. Barriers to the national health information system are also discussed, such as the asymmetry of costs and benefits of electronic health records and the absence of interoperability standards.
The Kingdom of Tonga has had one of the best overall levels of health within the Pacific as a result of a dramatic reduction in communicable diseases and maternal and child mortality since the 1950s. It is also on target to achieve the Millennium Development Goals (MDG) around maternal and child mortality. Adapting its strong primary health-care system to deal with the large financial burden associated with chronic and noncommunicable diseases and ensuring quality primary health-care services in remote areas are the main health sector challenges facing Tonga.
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINOCNseg
The document discusses challenges and opportunities related to medical devices in the US healthcare system. It provides background on AHIP and trends in US healthcare spending and insurance coverage. It then discusses the medical device industry and market, FDA regulation of devices, payment reform efforts toward value-based care, and examples of alternative payment models like bundled payments that aim to reduce costs and improve outcomes.
This document summarizes 10 health innovations and trends to watch in 2010, including: 1) "Hello Health" franchised primary care practices with online tools and direct payments, 2) use of surgical checklists to improve safety, 3) mobile health applications like HealthMap for disease surveillance, 4) direct-to-consumer genetic testing providing personalized health information, 5) "reverse innovations" developed first for emerging markets, 6) services generating personalized care plans from health data, 7) point-of-care diagnostic technologies, 8) the University of Toronto's crowdsourcing of health system ideas, 9) the growth of mobile health applications, and 10) patient data sharing communities like PatientsLikeMe. These innovations aim to improve health
This document provides an overview of health technology assessment (HTA) through a presentation given at the 62nd Session of the WHO Regional Committee for the Eastern Mediterranean. It defines HTA and its goals of providing evidence-informed input to decision makers and ensuring value for money. The presentation outlines how HTA is a multidisciplinary activity that examines the effects of health technologies on resources, costs, technical aspects, and other issues. It provides examples of HTA implementation from Thailand, Iran, and other countries. The presentation calls for all countries to establish national HTA programs and capacities and emphasizes that HTA is especially important for resource-limited settings. It outlines future commitments and steps from member states and WHO to strengthen HTA in the
Pauline Norris (University of Otago, New Zealand): Insight in the New Zealand health care system, with a focus on medicines – current status and developments. Kelan tutkimuksen "Lääke-euro talouden puristuksessa" -seminaari 3.6.2015, Helsinki.
New Zealand has a publicly funded healthcare system with universal coverage. It has a national electronic health record system including a unique patient identifier used for over 20 years. Most primary care practices use comprehensive electronic medical record systems integrated with labs and prescribing. Hospitals use integrated clinical workstations and patient administration systems. The national health IT plan aims to achieve high quality integrated care through shared care programs and national clinical systems like ePrescribing. Standards are developed through HISO and openEHR is used to define content and enable data sharing and secondary use through a shared health information platform.
This document discusses the Independent Hospital Pricing Authority's (IHPA) work on pricing reforms beyond 2020. Key points include:
1) IHPA sets national efficient prices, develops classification systems, and handles cross-border disputes to promote transparency, value, and efficiency in the public hospital system.
2) IHPA is moving public hospital funding toward an activity-based funding model, with blocks of funding still used in some areas. This has led to a significant slowdown in cost growth.
3) IHPA is developing pricing approaches to incentivize safety, quality and efficiency. This includes not funding episodes involving sentinel events, paying less for episodes complicated by hospital-acquired conditions,
The document discusses the OECD Recommendation on Health Data Governance. It notes that better policy frameworks are needed to make more effective use of health data. The recommendation was developed over two years with input from governments, civil society, and industry. It aims to establish national health data governance frameworks, promote privacy and data security, and enable cross-country research and statistics. The recommendation includes provisions around transparency, consent, oversight, and monitoring progress on implementation.
Spending reviews: OECD practices and applications for healthOECD Governance
This presentation was made by Ronnie DOWNES, OECD Secretariatat the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems held on 4-5 February 2016 at the OECD Conference Centre in Paris.
The drivers of public health spending: integrating policies and institutionsOECD Governance
This presentation was made by Joaquim Oliveira Martins at the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems, held on 4-5 February 2016 at the OECD Conference Centre in Paris.
The document provides an overview of health technology assessment (HTA) reports produced by the Malaysian Health Technology Assessment Section (MaHTAS). It discusses MaHTAS's functions, products, and processes for conducting HTAs. Key points include that MaHTAS has produced over 550 HTA reports since 1997 covering various health technologies. The document also outlines criteria for evaluating the quality of HTA reports based on a checklist from the International Network of Agencies for HTA, focusing on transparency around methods, sources of information, and conclusions.
Role of In Vitro Diagnostics in Saudi ArabiaSolidiance
Saudi Arabia’s healthcare system currently relies heavily on government funding, which accounts for 65% healthcare spending in the country. Healthcare trends in Saudi Arabia's, e.g. demographic shifts, high incidence rates of lifestyle related diseases, growing demand for private healthcare services, and strategic investments made by the government have driven demands for in vitro diagnostic (IVD) devices. Solidiance co-developed this exclusive white paper with Kind Abdulaziz Medical City and Abbott Diagnostics, highlighting the contribution, value and future of in vitro diagnostics in Saudi Arabia’s healthcare system. According to the report, the future looks bright for IVD in Saudi Arabia, however it depends on how fast it can be adopted and implemented in order to benefit the government, healthcare players seeking to improve and invest on the sector, and also the people.
This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian Towse
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
The document discusses healthcare spending in Malaysia relative to other countries. It notes that while Malaysia spends around 4% of GDP on healthcare, this is split almost evenly between public and private spending. There are pressures to increase healthcare spending due to an aging population and shift to chronic diseases. While additional investment may pay off through economic and health gains, funding needs to be increased through measures like taxes on tobacco or reducing fossil fuel subsidies. The large public-private divide and high out-of-pocket spending also need to be addressed through more strategic purchasing of healthcare services.
This presentation was made by Vlasta KOVACIC MEZEK, Slovenia, at the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems held on 4-5 February 2016 at the OECD Conference Centre in Paris.
Sri Lanka is well known for its better health indices when compared with other countries in South Asia. However, the burdens of Non Communicable Diseases (NCD) have increased rapidly during last two decades. NCDs such as neoplasms, cardiovascular diseases, diabetes and chronic respiratory pathologies recorded were 10.2, 41.7, 13.3 (related deaths per 100,000 population) respectively during the year 1990. However by 2009, the same NCDs recorded 18.5, 60.6, and 21.9 (related deaths per 100,000 populations) respectively according to the Annual Health Bullatin released by the Medical Statistics Unit - Ministry of Healthcare & Nutrition [1]. Most communicable diseases have been controlled successfully (e.g. Malaria, Polio) several infective diseases, such as, Tuberculosis and Leprosy has been re-emerged due to various reasons. Dengue is also still remains a major crisis in Sri Lankan health sector.
Health Information Systems have been shown an integral role in health systems in facing double burden of disease, specially quantifying the cost of care. Also, Health Information Systems are one of WHO's 6 building blocks for health system strengthening. This work investigates the Sri Lankan scenario empirically based on selected electronic health information systems to evaluate the effect of reducing uncertainty and promoting coordination in the clinical care pathway.
The document provides an overview of basic health economics concepts. It discusses 1) how health expenditures relate to overall economic growth, 2) how resources are allocated in healthcare systems to maximize efficiency, and 3) issues regarding the long-term sustainability of healthcare systems. Key points include how economic analysis can help optimize resource allocation to meet needs, how rising drug costs and an aging population impact sustainability, and the risk of a "trade war" over pharmaceutical prices between the US and other countries.
Professor Sue Hill OBE, Chief Scientific Officer for Englandrightcare
We are excited to introduce the NHS Atlas of Variation in Diagnostic Services, the latest publication in the series of impressive NHS Atlases, which have highlighted variation in the provision of healthcare services.
Diagnostic services are of great importance in the NHS because, when used correctly, they support or rule out potential diagnoses, and underpin the effective and efficient management of patient pathways.
Unwarranted variation in the rates of diagnostic testing is of the utmost relevance to individual patients with the over-use, as well as under-use, of diagnostic tests being potentially serious issues. For example, effective capacity planning in imaging services should enable improved patient access balanced against the need to avoid over-use of interventions that have the potential to cause harm, such as ionising radiation.
Chapter 13 national health information systemnaranbatn
1. The document discusses the national health information system in Korea and provides details on the community health information system, future e-health models, and hospital information systems.
2. It outlines Korea's plan for a national health information system, including developing health information standards, implementing an electronic health record system, and revising medical laws regarding e-health.
3. Barriers to the national health information system are also discussed, such as the asymmetry of costs and benefits of electronic health records and the absence of interoperability standards.
The Kingdom of Tonga has had one of the best overall levels of health within the Pacific as a result of a dramatic reduction in communicable diseases and maternal and child mortality since the 1950s. It is also on target to achieve the Millennium Development Goals (MDG) around maternal and child mortality. Adapting its strong primary health-care system to deal with the large financial burden associated with chronic and noncommunicable diseases and ensuring quality primary health-care services in remote areas are the main health sector challenges facing Tonga.
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINOCNseg
The document discusses challenges and opportunities related to medical devices in the US healthcare system. It provides background on AHIP and trends in US healthcare spending and insurance coverage. It then discusses the medical device industry and market, FDA regulation of devices, payment reform efforts toward value-based care, and examples of alternative payment models like bundled payments that aim to reduce costs and improve outcomes.
This document summarizes 10 health innovations and trends to watch in 2010, including: 1) "Hello Health" franchised primary care practices with online tools and direct payments, 2) use of surgical checklists to improve safety, 3) mobile health applications like HealthMap for disease surveillance, 4) direct-to-consumer genetic testing providing personalized health information, 5) "reverse innovations" developed first for emerging markets, 6) services generating personalized care plans from health data, 7) point-of-care diagnostic technologies, 8) the University of Toronto's crowdsourcing of health system ideas, 9) the growth of mobile health applications, and 10) patient data sharing communities like PatientsLikeMe. These innovations aim to improve health
MAPS2018 Keynote address on EY report: Life Sciences 4.0 – Securing value thr...EY
Summary: This keynote address presented by Pamela Spence, EY Global Life Sciences Leader (pspence2@uk.ey.com) at MAPS 2018 – the annual meeting for Medical Affairs Professional Society – discusses our latest life sciences report and the industry demands for a customer-focused, data driven approach to health care. We describe the accelerating pace of change as technological advances and the escalating expectations of payers, physicians and patient consumers are combining to disrupt the life sciences business model. Data and algorithms that maximize health outcomes based on individual needs and preferences are becoming the ultimate health care consumable. To create value now and in a future that we call Life Sciences 4.0, life sciences companies must build – or participate in – interoperable information systems that collect, combine and share data. For more on our report, Progressions 2018 – Life Sciences 4.0, please go to www.ey.com/progressions
Health Valley Event Presentatie Rob ten HoedtHealth Valley
1. Rob ten Hoedt, President of Medtronic Europe, gave a presentation on the medical technology industry and Medtronic's role in innovation in Europe.
2. Key trends in European healthcare include aging populations, rising costs, and a focus on prevention and chronic disease management outside hospitals.
3. Medtronic is developing innovative solutions like implantable devices, biologics, and wireless technologies to treat conditions like heart disease, diabetes, and neurological disorders.
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
The document discusses current challenges and future trends in clinical development from the perspective of a CRO. It notes that the global CRO market is large but fragmented, and outlines pressures on the pharmaceutical industry like high R&D costs, patent expirations, and regulatory demands. The text also examines trends towards more global, efficient trials using new technologies and less traditional geographies to address these challenges. It argues that collaboration between industry, regulators and CROs will be key to transforming clinical research methods.
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
The document discusses current challenges and future trends in clinical development from the perspective of a CRO. It notes that the global CRO market is large but fragmented, and outlines pressures on the pharmaceutical industry like high R&D costs, patent expirations, and regulatory demands. The text also examines trends towards more global, efficient trials using new technologies and less traditional geographies to address these challenges. It argues that collaboration between industry, regulators and CROs will be key to transforming clinical research processes to increase competitiveness and innovation.
Extended Real-World Data: The Life Science Industry’s Number One AssetHealth Catalyst
The life science industry has historically relied on sanitized clinical trials and commoditized data sources (largely claims) to inform its drug development process—an under-substantiated approach that didn’t reflect how a new drug would affect broader patient populations. In an effort to gain more accurate insight into the patient experience and bring drugs to market more efficiently and safely, the industry is now expanding into extended real-world data (RWD).
To access the needed breadth and depth of patient-centric data, life science companies must partner with a healthcare transformation company that has three key qualities:
A broad and deep data asset.
Extensive provider partnerships.
An outcomes-improvement engine to support the next generation of drug development.
We don’t have a functional competitive market in health care in the U.S. Consequently, many of the attributes of competitive markets that are beneficial in our lives are not present in health care. One significant negative externality of a dysfunctional market is an inability to discern quality. Consumerism is critical. Includes data and analysis from the 5TH ANNUAL HEALTHGRADES PATIENT SAFETY IN AMERICAN HOSPITALS STUDY – APRIL 2008
The document provides an overview of the key issues in the U.S. healthcare system and proposals for reform. It discusses problems like rising costs, uninsured populations, and disparities in quality. The reform proposals aim to expand coverage, reduce costs, and improve quality through mechanisms like insurance exchanges, individual and employer mandates, expanded Medicaid, and payment reforms. Stakeholders like insurers, providers, consumers would all be impacted by the reforms through changes to financing, coverage, and care delivery.
2016 IBM Interconnect - medical devices transformationElizabeth Koumpan
Emerging technologies such as Internet of Things, 3D Printing are driving the creation of new business models and forcing the Industry for transformation. The product centric model where the Industry main objective was to develop the device, is moving to software and services model, with the focus on Big Data & Analytics, Integration and Cloud.
The maturation of technologies such as social, mobile, analytics, cloud, 3D printing, bio- and nanotechnology are rapidly shifting the competitive landscape. These emerging technologies create an environment that is connected and open, simple and intelligent, fast and scalable. Organizations must embrace disruptive technologies to drive innovation
1) The presentation discusses various considerations for leading a healthcare organization from 2013-2018, including the integration of technology and data, the influence of consumers, and opportunities to improve efficiency.
2) Several types of companies are discussed that will play roles in the healthcare marketplace, including "fixers" that simplify the system, "implementers" that assist with regulations, and "connectors" that link information.
3) Technology is transforming healthcare through increased online health information, use of mobile apps, and tools that empower patients to better manage chronic conditions.
This document summarizes a presentation on the state of data science and healthcare analytics. It discusses:
1) The increasing sophistication of analytics in healthcare, from basic reporting to predictive modeling.
2) New opportunities for applying data science and analytics across healthcare stakeholders like payers, providers, life sciences companies, consumers, and employers.
3) The future of data science and analytics, including new data sources, artificial intelligence applications, and "algorithmic medicine" to personalize treatment through aggregating diverse data on individual patients.
Surveys a series of ethical, economic, clinical and also safety issues relating to the application of informatics to healthcare, focusing especially on the role of informatics in the Patient Protection and Affordable Care Act. Talk presented in the University at Buffalo Clinical/Research Ethics Seminar - Ethics, Informatics and Obamacare, November 20, 2012. Slides are available here: http://ontology.buffalo.edu/13/ethics-informatics-obamacare.pptx
"Healthcare Services at Merck & Co". Presentation by Guy Eiferman, President of Healthcare Services and Solutions, Merck & Co., made at the mHealth Israel Investors Summit, June 29, 2015, in Jerusalem
Big data in healthcare refers to large, diverse, and complex datasets that are difficult to analyze using traditional methods. The healthcare industry generates huge amounts of data from sources like electronic health records, medical imaging, and fitness trackers. Analyzing this big data can help improve patient outcomes, reduce costs, and advance personalized medicine. However, healthcare also faces challenges like data silos, privacy concerns, and resistance to change. Opportunities include disease prediction and prevention, reducing readmissions and fraud, and optimizing care through remote monitoring. Some organizations are starting to see benefits from big data initiatives focused on areas like evidence-based treatment and integrated health records.
What eHealth strategies work and do not work, and what should be implemented to effectively meet these healthcare “transformational” imperatives?. Crawford J. eHealth week 2010 (Barcelona: CCIB Convention Centre; 2010)
Asia HealthTech Investments by Julien de Salaberry (30 June 2015)KickstartPH
Kickstart Ventures' 2nd HealthTech Forum featured Julien de Salaberry, a globally-recognised expert on healthcare and technology.
Julien, the Chief Innovation Officer and Founder of The Propell Group (based in Singapore), talked about healthcare trends in Southeast Asia and how “frugal innovation" can be done in healthcare delivery.
And yeah, if you've got an interesting healthtech startup, message us at info@kickstart.ph. #startupPH
Health Technology Assessment- Overviewshashi sinha
This document discusses health technology assessment (HTA) in India. It provides an outline of HTA and its potential applications. HTA is defined as a multidisciplinary process that systematically evaluates the medical, social, economic and ethical issues related to a health technology. The document discusses the need for HTA in India given rising healthcare costs and limited resources. It outlines the HTA process, including defining the research question, criteria for study inclusion/exclusion, literature searches, and steps like systematic reviews and economic evaluations. Key applications of HTA mentioned are assessing new technologies for investment/disinvestment and informing priority setting and coverage decisions.
Digitization is bringing a sea change to a U.S. healthcare industry already facing waves of uncertainty. By taking the right steps, this can be a major opportunity for industry players.
Forecasting the future of any industry is difficult, none more so right now than healthcare in the United States. There are countless reasons why healthcare will look different in the near future, not least of which being the country's movement toward national coverage. However, digital transformation—the cumulative change that comes when digital technologies are introduced wholesale into an established industry—is poised to have an even bigger impact. For the U.S. healthcare industry, digital technology will be transformational, cutting healthcare delivery costs, eliminating errors through improved electronic medical records, and establishing routinized, evidence-based approaches to treatment.
Digital forces are pulling at the industry and significantly altering services, products, innovation, delivery, and remuneration (see figure). There are digitally integrated healthcare providers, digital medical devices and technologies, and digital delivery and monitoring of home healthcare. In addition, new ideas are emanating from developing markets, agile competitors are embracing technology, and a digital-friendly federal administration is pushing innovation. And don't forget the digital consumer who is used to digital banking, digital retailing, and digital education, and expects digital healthcare.
- See more at: http://www.atkearney.com/paper/-/asset_publisher/dVxv4Hz2h8bS/content/digital-healthcare-or-bust-in-america/10192#sthash.gP6B4uWR.dpuf
Similar to Advanced health technologies and their budgetary implications - Valérie Paris, OECD (20)
The document discusses transparency and oversight of political party financing. It finds that financial contributions to political parties are not fully transparent and are still vulnerable to political and foreign influence. Additionally, financial reports from political parties are not always publicly available or submitted on time according to regulations.
Summary of the OECD expert meeting: Construction Risk Management in Infrastru...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
Using AI led assurance to deliver projects on time and on budget - D. Amratia...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
ECI in Sweden - A. Kadefors, KTH Royal Institute of Technology, Stockholm (SE)OECD Governance
This document discusses different construction project delivery and payment models. It begins by outlining common delivery models like design-bid-build and design-build. It then explains different payment methods that can be used like fixed price, unit prices, and cost-reimbursable. The document also discusses pricing strategies and how they relate to risk transfer between parties. It provides details on collaborative models like early contractor involvement and discusses selecting the optimal contract based on a client's project risks, desired influence, and market conditions.
Building Client Capability to Deliver Megaprojects - J. Denicol, professor at...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
Procurement strategy in major infrastructure: The AS-IS and STEPS - D. Makovš...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
Procurement of major infrastructure projects 2017-22 - B. Hasselgren, Senior ...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
ECI Dutch Experience - A. Chao, Partner, Bird&Bird & J. de Koning, Head of Co...OECD Governance
This document discusses ECI Dutch experience with collaborative contracting. It mentions a McKinsey report from 2018 on collaborative contracting and recent developments in the field. Finally, it provides lessons learned from a project in Amsterdam called Bouwteam De Nieuwe Zijde Noord.
ECI in Sweden - A. Kadefors, KTH Royal Institute of Technology, StockholmOECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
EPEC's perception of market developments - E. Farquharson, Principal Adviser,...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
Geographical scope of the lines in Design and Build - B.Dupuis, Executive Dir...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
Executive Agency of the Dutch Ministry of Infrastructure and Water Management...OECD Governance
Presented at the OECD expert meeting "Construction Risk Management in Infrastructure Procurement: The Loss of Appetite for Fixed-Price Contracts", held on 17 May 2023 at the OECD, Paris and online.
Presentation of OECD Government at a Glance 2023OECD Governance
Paris, 30 June, 2023
Presentation by Elsa Pilichowski, Director for Public Governance, OECD.
The 2023 edition of Government at a Glance provides a comprehensive overview of public governance and public administration practices in OECD Member and partner countries. It includes indicators on trust in public institutions and satisfaction with public services, as well as evidence on good governance practices in areas such as the policy cycle, budgeting, procurement, infrastructure planning and delivery, regulatory governance, digital government and open government data. Finally, it provides information on what resources public institutions use and how they are managed, including public finances, public employment, and human resources management. Government at a Glance allows for cross-country comparisons and helps identify trends, best practices, and areas for improvement in the public sector.
See: https://www.oecd.org/publication/government-at-a-glance/2023/
The Protection and Promotion of Civic Space: Strengthening Alignment with Int...OECD Governance
Infographics from the OECD report "The Protection and Promotion of Civic Space Strengthening Alignment with International Standards and Guidance".
See: https://www.oecd.org/gov/the-protection-and-promotion-of-civic-space-d234e975-en.htm
OECD Publication "Building Financial Resilience
to Climate Impacts. A Framework for Governments to manage the risks of Losses and Damages.
Governments are facing significant climate-related risks from the expected increase in frequency and intensity of cyclones, floods, fires, and other climate-related extreme events. The report Building Financial Resilience to Climate Impacts: A Framework for Governments to Manage the Risks of Losses and Damages provides a strategic framework to help governments, particularly those in emerging market and developing economies, strengthen their capacity to manage the financial implications of climate-related risks. Published in December 2022.
OECD presentation "Strengthening climate and environmental considerations in infrastructure and budget appraisal tools"
by Margaux Lelong and Ana Maria Ruiz during the 9th Meeting of the OECD Paris Collaborative on Green Budgeting held on 17 and 18 of April 2023 in Paris.
OECD presentation "Building Financial Resilience to Climate Impacts. A Framework to Manage the Risks of Losses and Damages" by Andrew Blazey, Stéphane Jacobzone and Titouan Chassagne. Presented during the 9th Meeting of the OECD Paris Collaborative on Green Budgeting held on 17 and 18 of April 2023 in Paris
OECD Presentation "Financial reporting, sustainability information and assurance" by Peter Welch during the 5th Session during the 9th Meeting of the OECD Paris Collaborative on Green Budgeting held on 17 and 18 of April 2023 in Paris
This document summarizes developments in sovereign green bond markets. It discusses approaches to incorporating environmental, social, and governance (ESG) factors into public debt management. Sovereign green bond issuance has grown significantly in both advanced and emerging economies since 2016. Green bonds make up the largest share of the labeled bond market. Major benefits of sovereign green bonds include their positive impact on creditworthiness and alignment with ESG policies. However, issuers also face challenges such as additional costs and complexity of the issuance process. Common leading practices emphasize transparency, collaboration, and commitment to reporting.
Bharat Mata - History of Indian culture.pdfBharat Mata
Bharat Mata Channel is an initiative towards keeping the culture of this country alive. Our effort is to spread the knowledge of Indian history, culture, religion and Vedas to the masses.
Indira awas yojana housing scheme renamed as PMAYnarinav14
Indira Awas Yojana (IAY) played a significant role in addressing rural housing needs in India. It emerged as a comprehensive program for affordable housing solutions in rural areas, predating the government’s broader focus on mass housing initiatives.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Presentation by Rebecca Sachs and Joshua Varcie, analysts in CBO’s Health Analysis Division, at the 13th Annual Conference of the American Society of Health Economists.
The Power of Community Newsletters: A Case Study from Wolverton and Greenleys...Scribe
YOU WILL DISCOVER:
The engaging history and evolution of Wolverton and Greenleys Town Council's newsletter
Strategies for producing a successful community newsletter and generating income through advertising
The decision-making process behind moving newsletter design from in-house to outsourcing and its impacts
Dive into the success story of Wolverton and Greenleys Town Council's newsletter in this insightful webinar. Hear from Mandy Shipp and Jemma English about the newsletter's journey from its inception to becoming a vital part of their community's communication, including its history, production process, and revenue generation through advertising. Discover the reasons behind outsourcing its design and the benefits this brought. Ideal for anyone involved in community engagement or interested in starting their own newsletter.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Presentation by Julie Topoleski, CBO’s Director of Labor, Income Security, and Long-Term Analysis, at the 16th Annual Meeting of the OECD Working Party of Parliamentary Budget Officials and Independent Fiscal Institutions.
How To Cultivate Community Affinity Throughout The Generosity JourneyAggregage
This session will dive into how to create rich generosity experiences that foster long-lasting relationships. You’ll walk away with actionable insights to redefine how you engage with your supporters — emphasizing trust, engagement, and community!
Advanced health technologies and their budgetary implications - Valérie Paris, OECD
1. Valérie Paris, OECD
6th MEETING OF THE OECD JOINT NETWORK ON FISCAL
SUSTAINABILITY OF HEALTH SYSTEMS
OECD, Paris, 19 September 2017
A Look into the Future.
Advanced Health Technologies and
their budgetary Implications
2. Health technologies have generated health benefits
… and contributed to health care costs
0
50000
100000
150000
1960s 1970s 1980s 1990s
Spending per life year gained
(2002 USD)
65 years 45 years 15 years Newborn
Adapted from: Cutler, D., A. Rosen and S. Vijan (2006), “The Value of Medical Spending in the United States, 1960–2000”, New England Journal of Medicine, Vol. 355,
No. 9, pp. 920-927.
Longitudinal trends in the costs per year of life gained in four age groups in the United States
2
Technology has improved health systems capacity to diagnose and treat
diseases and help patients
Technological progress contributed by 20% to 70% of health spending
growth depending on estimates
Health care costs have shown decreasing returns between 1960 and 1990
3. Technologies have different value for health systems
High-value
technology
(type A)
Process innovation
- Aseptic technique; Wound sterilisation
Low-cost, highly effective
- Aspirin and beta blockers
- Vaccines
- Public health and preventive interventions
High-cost, highly effective, clearly defined target population
- Antiretroviral treatment
- Cataract removal
- New-generation hepatitis C medication
Effective
technology with a
risk of expanding
use
(type B)
Effective for some patients, but broad application diminishes marginal and overall
benefit
- Diagnostic imaging
- Cardiac catheterisation and angioplasty
- Laparoscopic surgery
- Intensive care (end of life)
Low-value
technology
(type C)
Little evidence of effectiveness or low effectiveness
- Expensive substitutes (e.g. robot-assisted surgery for some indications)
- Spinal surgery in low back pain
- Many diagnostic tests
- Many high-cost cancer drugs
- Pulmonary Artery Catheterisation (PAC)
Source: Based on Chandra, A. and J. Skinner (2012), “Technology Growth and Expenditure Growth in Health
Care”, Journal of Economic Literature, Vol. 50, No. 3, pp. 645-680; and Chandra, A. and J. Skinner (2008),
“Technology and Expenditure Growth in Health Care”, NBER Working Paper, Cambridge, United States.
3
4. • Treatments are increasingly tailored to individual patients (precision
medicine)
• In 2015, 165 000 mobile apps were available (x2 since 2013) – not
all MD and most are not covered... but need to be reliable,
performant, safe and to guarantee protection of personal data. This
is not always the case.
• Combination products (drug+medical device; medical device + IT,
etc..) blur traditional lines between separate technologies
• Disruptive technologies (3D bio printing, IA) are arriving
4
New technologies are flooding the market, raising new
challenges for policy makers,
5. • More than 200 000 medical devices - about 4 500
new devices are approved in a given year.
• New products, which combine drugs and medical
devices or medical devise and digital tools
• Regulation of MD weaker than that of
pharmaceuticals (because of SME, short life-cycle).
• Performances of MD not really monitored after
market approval, only serious safety concerns.
• Yet, relative performances of competing medical
devices may be very different (e.g. hip prostheses).
5
Challenges raised by medical devices
6. 6
What can we do?
Harness health data to assess the performance
of medical devices in clinical practice...
… and better guide clinical practice and
inform coverage/disinvestment policies
Assess the potential of bundled and
outcome-based payments
7. What can we do? Promote a life-cycle
approach for HTA, coverage and funding
7
New medical device (and procedure)
Coverage, funding & reimbursement
Effectiveness – clinical utility
Review
Regulators
Payers
Evidence gathering & analysis
• Administrative/activity data
• Clinical , imaging and lab data
• Patient-reported data
• Cost data
• Registries
• Mortality data
Market authorisation
Safety - performance - effectiveness
Phased entry
Updating reimbursement
schedules & financing model
Governance
• Clear objectives and principles
• Transparency
• Independence
• Stakeholder engagement
Health information
infrastructure
• Legislative enablers
• Technical capacity
• Unique patient identifier
• Unique device identifier
• Electronic health record
• Human capital and expertise
CE
D
8. Challenges raised by pharmaceuticals
0
50
100
150
200
250
300
350
400
2000200120022003200420052006200720082009201020112012201320142015
Number of
orphan drug
designations/ap
provals
US designations EU designations
US approvals EU approvals
Source: Based on FDA Office of Orphan
Drug Products; European Commission.
Number of orphan drug designations
& approvals in the United States and
the European Union, 2000-15
8
• Medicines increasingly target small
populations
• ¼ of medicines approved in the US
are targeted therapies in 2015 (often
in oncology)
• Almost one half of medicines
approved in the US are orphan drugs.
• These drugs typically have high prices,
are often not cost-effective
• High prices compromise access
9. Health gains are not always
commensurate to price increases
• Launch list prices of new oncology
drugs in the US, adjusted for
inflation and for year of life saved,
have been multiplied by four in 20
years
• Oncology drugs account for 1/3 of
new active substances approved
annually in the US and 1/3 of
products in development
• New anti-cancer drugs are
generally not cost-effective at
« standard » cost-effectiveness
thresholds
These trends compromise
access, efficiency (and
sustainability?) of health
spending
Launch price of an oncology drugs per life-
year gained, in 2013 USD, in the United States
10. What is the right price for innovative
medicines?
10
https://www.forbes.com/sites/matthewherper/2017/08/30/novartis-ceos-dilemma-is-475000-too-much-for-a-leukemia-breakthrough-
or-is-it-not-enough/#86f550556ec5
https://www.statnews.com/2017/08/31/475000-price-tag-new-cancer-drug-crazy-meh/
11. When is expensive too expensive? The price of the
first DAA for hepatitis C
Would countries have
reacted differently if
better prepared?
How will we react if a
miracle drug cures HIV or
if a useful drug can
• Sofosbuvir’s list price (84 000
USD/cure) at market entry
• Game changer for patients
• Unaffordable budget impact
• First experience of “rationing in
wealthy” countries’ and price
negotiations
• Record profit for the company
• Now: competition has reduced
prices
12. What can we do?
12
Reduce research and development costs (e.g.
harmonisation of approval standards)
Improve (joint) horizon scanning
Envisage cooperation in HTA / cooperation in negotiation
/ cooperation in procurement
Define clear , transparent and consensual criteria for
coverage or pricing and not depart from them
Increase transparency in pricing / Establish best practices
for managed entry agreements
Increase competition in on-patent markets (tendering,
bundled payments)
Exploit the potential of routinely-collected data to adjust
coverage conditions
13. Using health data can improve care
and build knowledge
There are obstacles to using health data
effectively in most countries
Better policy frameworks are needed to get
more out of health data
Harness the potential of health data is crucial
14. Countries are not all ready to use health data
Australia Austria
Canada
Chile
Croatia
Czech Rep.
Denmark
Estonia
Finland
France
Greece
Iceland
Ireland Israel
Japan
Latvia Luxembourg
Mexico
New
Zealand
Norway
Poland
Singapore
Slovakia
Spain
Sweden
Switzerland
UK
Eng.
UK N. Ireland
UK
Scot.
United
States
Datagovernancereadiness
Technical and operational readinessLow High
LowHigh
Source: HCQI Survey of Electronic Health Record System Development and Use (2016).
Data governance and technical/operational readiness to develop national
information from EHRs, 2016
14
15. 1. Establish national health data governance frameworks
• Encourage availability & use of health data to advance public policy objectives
• Promote privacy protection & data security
2. Harmonise frameworks between countries
• Enable multi-country statistical and research projects
OECD Council recommendations for health data governance